Entrectinib received accelerated approval from the FDA in 2019 for adults with met-astatic NSCLC with ROS1-positive tumors and those with solid tumors that had a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. Here, ROS1 is linked to non-small cell lung carcinoma.